Ubiquitins and PROTAC®: A New Frontier in Targeted Therapy

Ubiquitins are essential proteins that regulate cellular functions by marking other proteins for degradation, thereby maintaining homeostasis. Targeted Protein Degradation (TPD) leverages this principle through Proteolysis Targeting Chimera (PROTAC®) technology, which selectively degrades pathological proteins by linking them to E3 ubiquitin ligases. The major advantage of PROTACs is the ability to overcome drug resistance and degrade “undruggable” target proteins, making it a novel tool for targeted therapy. Currently, most PROTACs are in the clinical trial stage, mainly targeting cancer. SignalChem Biotech supports research into new PROTAC®-based therapies by offering a diverse array of ubiquitin enzymes, including CRBN/DDB1/Cul4A/Rbx1 complexes, E1 activating enzymes, E2 conjugating enzymes, E3 ligases, and deubiquitinase enzymes, which are crucial for the development of innovative therapeutics.